Lördag 26 April | 03:13:21 Europe / Stockholm

Svenska | English

Hutchmed (China)

Kalender

	Est. tid*
2025-05-13	N/A	Årsstämma
2025-03-31	-	Extra Bolagsstämma
2024-08-01	-	Kvartalsrapport 2024-Q2
2019-05-30	-	Split HCM 1:10

Beskrivning

Land	Caymanöarna
Lista	52
Sektor	Hälsovård
Industri	Vård & Omsorg

Filter

År

Typ

Språk

Rensa

2025-04-24 08:00:13 HUTCHMED - Data to be Presented at AACR 2025 237,00 GBP | +2,16%

2025-04-24 02:00:00 HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 237,00 GBP | +2,16%

2025-04-22 08:00:15 HUTCHMED Completes Enrollment of Phase II Study 235,00 GBP | +10,85%

2025-04-22 02:00:00 HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China 235,00 GBP | +10,85%

2025-04-07 10:30:00 2024 Annual Report and Notice of AGM 195,00 GBP | -12,75%

2025-03-31 11:30:00 Extraordinary General Meeting – Poll Results 232,00 GBP | -2,11%

2025-03-21 11:00:01 NMPA Conditional Approval for TAZVERIK® 227,00 GBP | -9,20%

2025-03-21 11:00:00 HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma 227,00 GBP | -9,20%

2025-03-20 10:30:01 Retirement of Independent Non-executive Directors 250,00 GBP | +2,04%

2025-03-20 10:30:00 Intended Retirement of Independent Non-executive Directors and changes of composition of board committees 250,00 GBP | +2,04%

2025-03-20 08:00:13 HUTCHMED Highlights Savolitinib SAVANNAH Phase II 250,00 GBP | +2,04%

2025-03-20 01:00:00 HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 250,00 GBP | +2,04%

2025-03-19 14:45:00 Publication of Form 20-F 245,00 GBP | +6,52%

2025-03-19 12:00:00 2024 Final Results and Business Updates 245,00 GBP | +6,52%

2025-03-19 12:00:00 HUTCHMED Reports 2024 Full Year Results and Provides Business Updates 245,00 GBP | +6,52%

2025-03-19 08:00:12 Phase II/III Study of Fruquintinib and Sintilimab 245,00 GBP | +6,52%

2025-03-19 01:00:00 HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China 245,00 GBP | +6,52%

2025-03-14 10:30:00 Adoption of the 2025 Long Term Incentive Plan 243,00 GBP | +2,53%

2025-03-14 10:30:00 Vesting of awards under Long Term Incentive Plan 243,00 GBP | +2,53%

2025-03-13 10:30:00 Notice of Extraordinary General Meeting 237,00 GBP | -2,07%

2025-03-06 11:00:00 Completed Enrollment of Phase II Study 248,00 GBP | -4,25%

2025-03-06 11:00:00 HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China 248,00 GBP | -4,25%

2025-03-05 11:00:00 Directorate Change 259,00 GBP | +3,19%

2025-03-05 11:00:00 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee 259,00 GBP | +3,19%

2025-03-03 08:00:10 Overseas Regulatory Announcement 257,00 GBP | -3,38%

2025-02-28 16:00:01 Overseas Regulatory Announcement 266,00 GBP | -0,75%

2025-02-19 09:30:01 Notice of Results 232,00 GBP | +6,42%

2025-02-19 09:30:00 HUTCHMED to Announce 2024 Final Results 232,00 GBP | +6,42%

2025-01-28 10:00:00 Overseas Regulatory Announcement 218,00 GBP | -0,46%

2025-01-14 05:00:00 HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC 252,00 GBP | +4,13%

2025-01-02 01:00:00 HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy 247,00 GBP | +5,11%

2025-01-01 11:46:43 HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

2024-12-13 01:00:00 HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) 247,00 GBP | -1,59%

2024-12-12 05:00:00 HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy 251,00 GBP | -3,46%

2024-12-03 11:00:00 HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer 279,00 GBP | -0,36%

2024-11-28 11:30:00 HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms 277,00 GBP | -4,48%

2024-11-22 05:30:00 HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan 278,00 GBP | -1,07%

2024-11-20 10:30:00 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee 284,00 GBP | +9,23%

2024-11-06 05:00:00 HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress 284,00 GBP | -0,70%

2024-10-31 09:30:00 HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda 286,00 GBP | -2,05%

2024-10-16 06:30:00 HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial 303,00 GBP | +6,69%

2024-09-24 09:00:00 HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda 258,00 GBP | +1,98%

2024-09-09 02:00:00 HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer 261,00 GBP | -0,38%

2024-08-30 06:30:00 HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China 262,00 GBP | -2,96%

2024-08-21 10:30:00 HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia 273,00 GBP | -1,44%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Hutchmed (China)

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden